Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T02:44:20.477Z Has data issue: false hasContentIssue false

Chapter 8 - Mental Health in Parkinson’s Disease

from Section 1 - Epidemiology and Types of Disorders

Published online by Cambridge University Press:  12 September 2020

By
Shoned Jones ,
Kelli M Torsney ,
Lily Scourfield ,
Katie Berryman  and
Emily J Henderson
Edited by
Julian C. Hughes  and
Philippa Lilford
Julian C. Hughes
Affiliation:
University of Bristol
Philippa Lilford
Affiliation:
Severn Deanery, University of Bristol
Get access

Summary

Idiopathic Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD), and motorically it is characterized by tremor, ridigity, bradykinesia, and postural instability. Whilst it was historically considered to be a movement disorder there are multiple non-motor symptoms, which often precede the motor symptoms by years or even decades. These include dysautonomia, sleep disturbances, neuropsychiatric disturbances, pain, and sensory problems. These have a negative effect on quality of life and are associated with overall higher carer burden and, potentially, higher care costs whilst being frequently undeclared by patients.

Type
Chapter
Information
Clinical Topics in Old Age Psychiatry , pp. 116 - 128
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Klingelhoefer, L, Reichmann, H. Pathogenesis of Parkinson disease: the gut-brain axis and environmental factors. Nat Rev Neurol 2015; 11: 625–36.CrossRefGoogle ScholarPubMed
Chaudhuri, KR, Prieto-Jurcynska, C, Naidu, Y et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010 30; 25: 704–9.Google Scholar
Politis, M, Wu, K, Molloy, S et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 2010; 25: 1646–51.Google Scholar
Weintraub, D, Burn, DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022–31.Google Scholar
Perepezko, K, Hinkle, JT, Shepard, MD et al. Social role functioning in Parkinson’s disease: a mixed-methods systematic review. Int Journal Geriatr Psychiatry 2019; 34: 1128–38.CrossRefGoogle ScholarPubMed
Parkinson, J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817.Google Scholar
Reijnders, JSAM, Ehrt, U, Weber, WEJ, Aarsland, D, Leentjens, AFG. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008; 23: 183–9.Google Scholar
Huse, D, Schulman, K, Orsini, L et al. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2005; 20: 1449–54.Google Scholar
Findley, L, Eichhorn, T, Janca, A et al. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002; 17: 60–7.Google Scholar
Dissanayaka, NNW, Sellbach, A, Silburn, PA et al. Factors associated with depression in Parkinson’s disease. J Affect Disord 2011; 132: 82–8.CrossRefGoogle ScholarPubMed
Pagonabarraga, J, Kulisevsky, J, Strafella, AP, Krack, P. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14: 518–31.Google Scholar
Shulman, L, Taback, R, Rabinstein, A, Weiner, W. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Park Relat Disord 2002; 8: 193–7.Google Scholar
Marsh, L, McDonald, WM, Cummings, J et al. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148–58.CrossRefGoogle ScholarPubMed
Riedel, O, Klotsche, J, Spottke, A et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010; 257: 1073–82.CrossRefGoogle Scholar
van der Velden, RMJ, Broen, MPG, Kuijf, ML, Leentjens, AFG. Frequency of mood and anxiety fluctuations in Parkinson’s disease patients with motor fluctuations: a systematic review. Mov Disord 2018; 33: 1521–7.Google Scholar
Barone, P, Poewe, W, Albrecht, S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.Google Scholar
Richard, IH, Kurlan, R, Tanner, C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 48: 1070–7.CrossRefGoogle Scholar
Ghazi-Noori, S, Chung, TH, Deane, K, Rickards, HE, Clarke, CE. Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003; Issue 2. Art. No.: CD003465. [Republished in 2010 with no changes to the conclusions.]Google Scholar
Starkstein, SE, Brockman, S. Management of depression in Parkinson’s Disease: a systematic review. Mov Disord Clin Pract 2017; 4: 470–7.CrossRefGoogle ScholarPubMed
den Brok, MGHE, van Dalen, JW, van Gool, WA, Moll van Charante EP, de Bie RMA, Richard E. Apathy in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2015; 30: 759–69.CrossRefGoogle ScholarPubMed
Marin, RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243–54.Google Scholar
Pagonabarraga, J, Kulisevsky, J, Strafella, AP, Krack, P. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14: 518–31.Google Scholar
Aarsland, D, Brønnick, K, Alves, G et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009; 80: 928–30.CrossRefGoogle ScholarPubMed
Carlson, JM, Foti, D, Mujica-Parodi, LR, Harmon-Jones, E, Hajcak, G. Ventral striatal and medial prefrontal BOLD activation is correlated with reward-related electrocortical activity: a combined ERP and fMRI study. Neuroimage 2011; 57: 1608–16.Google Scholar
Shulman, LM, Armstrong, M, Ellis, T et al. Disability rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2016; 31: 1455–65.CrossRefGoogle ScholarPubMed
Carrozzino, D. Clinimetric approach to rating scales for the assessment of apathy in Parkinson’s disease: a systematic review. Prog NeuroPsychopharmacology Biol Psychiatry 2019; 94: 109641.Google Scholar
Chaudhuri, KR, Martinez-Martin, P, Antonini, A et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Park Relat Disord 2013; 19: 660–5.Google Scholar
Devos, D, Moreau, C, Maltête, D et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85: 668–74.Google Scholar
Dissanayaka, NNW, Sellbach, A, Matheson, S et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord 2010; 25: 838–45.Google Scholar
Broen, MPG, Narayen, NE, Kuijf, ML, Dissanayaka, NNW, Leentjens, AFG. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2016; 31: 1125–33.Google Scholar
Pontone, GM, Williams, JR, Anderson, KE et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord 2009; 24: 1333–8.CrossRefGoogle ScholarPubMed
Leentjens, AFG, Dujardin, K, Marsh, L et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2008; 23: 2015–25.Google ScholarPubMed
Prediger, RDS, Matheus, FC, Schwarzbold, ML, Lima, MMS, Vital, MABF. Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology 2012; 62: 115–24.CrossRefGoogle ScholarPubMed
Menza, MA, Sage, J, Marshall, E, Cody, R, Duvoisin, R. Mood changes and ‘on‐off ’ phenomena in Parkinson’s disease. Mov Disord 1990; 5: 148–51.CrossRefGoogle ScholarPubMed
Koychev, I, Okai, D. Cognitive–behavioural therapy for non-motor symptoms of Parkinson’s disease: a clinical review. Evid-Based Ment Health 2017; 20: 15–20.Google Scholar
Ravina, B, Marder, K, Fernandez, HH et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH Work Group. Mov Disord 2007; 22: 1061–8.Google Scholar
Gibson, G, Mottram, PG, Burn, DJ et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson’s disease: a longitudinal 4-year study. Int J Geriatr Psychiatry 2013; 28: 626–31.Google Scholar
Forsaa, EB, Larsen, JP, Wentzel-Larsen, T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996–1001.CrossRefGoogle ScholarPubMed
Marsh, L, Williams, J, Rocco, M, Grill, S, Munro, C, Dawson, T. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293–300.Google Scholar
Aarsland, D, Marsh, L, Schrag, A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 2009; 24: 2175–86.Google Scholar
Burn, D, Emre, M, McKeith, I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21: 1899–907.Google Scholar
Cummings, J, Isaacson, S, Mills, R et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533–40.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence. Parkinson’s Disease in Adults. NICE Guideline (NG71). London: NICE; July 2017. www.nice.org.uk/guidance/ng71/evidence/full-guideline-pdf-4538466253 [last accessed 6th February 2020.]Google Scholar
Levy, G, Tang, M-X, Louis, ED et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708–13.Google Scholar
Aarsland, D, Larsen, JP, Karlsen, K, Lim, NG, Tandberg, E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866–74.Google Scholar
Aarsland, D, Larsen, J, Tandberg, E, Aake, K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938–42.Google Scholar
Janvin, CC, Larsen, JP, Aarsland, D, Hugdahl, K. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 2006; 21: 1343–9.Google Scholar
Lawson, RA, Yarnall, AJ, Duncan, GW et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry 2017; 88: 648–52.CrossRefGoogle ScholarPubMed
Yarnall, AJ, Rochester, L, Burn, DJ. Mild cognitive impairment in Parkinson’s disease. Age Ageing 2013; 42: 567–76.CrossRefGoogle ScholarPubMed
Litvan, I, Aarsland, D, Adler, CH et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.Google Scholar
Williams-Gray, CH, Mason, SL, Evans, JR et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258–64.Google Scholar
Auyeung, M, Tsoi, T, Mok, V et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry 2012; 83: 607–11.Google Scholar
Hely, MA, Reid, WGJ, Adena, MA, Halliday, GM, Morris, JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.Google Scholar
Williams-Gray, CH, Foltynie, T, Brayne, CEG, Robbins, TW, Barker, RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007; 130: 1787–98.Google Scholar
Williams-Gray, CH, Evans, JR, Goris, A et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958–69.Google Scholar
Waxman, EA, Giasson, BI. Molecular mechanisms of α-synuclein neurodegeneration. Biochim Biophys Acta – Molecular Basis of Disease 2009; 1792: 616–24.Google ScholarPubMed
Cilia, R, Tunesi, S, Marotta, G et al. Survival and dementia in GBA-associated Parkinson’s disease: the mutation matters. Ann Neurol 2016; 80: 662–73.Google Scholar
Grünewald, A, Kasten, M, Ziegler, A, Klein, C. Next-generation phenotyping using the Parkin example: time to catch up with genetics. JAMA Neurol 2013; 70: 1186–91.Google Scholar
Wang, HF, Yu, JT, Tang, SW et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86: 135–43.Google Scholar
Murray, DK, Sacheli, MA, Eng, JJ, Stoessl, AJ. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl Neurodegener 2014; 3: 5. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/2047-9158-3-5 [last accessed on 6th February 2020].CrossRefGoogle ScholarPubMed
Leung, IH, Walton, CC, Hallock, H et al. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology 2015; 85: 1843–51.CrossRefGoogle ScholarPubMed
Vardy, ERLC, Teodorczuk, A, Yarnall, AJ. Review of delirium in patients with Parkinson’s disease. J Neurol 2015: 262: 2401–10.Google Scholar
Serrano-Dueñas, M, Bleda, MJ. Delirium in Parkinson’s disease patients. A five-year follow-up study. Park Relat Disord 2005; 11: 387–92.Google Scholar
Umemura, A, Oeda, T, Tomita, S, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS One 2014; 9(6): e94944. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094944 [last accessed on 6th February 2020].Google Scholar
Weintraub, D, Koester, J, Potenza, MN et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.Google Scholar
Okai, D, Askey-Jones, S, Samuel, M et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013; 80: 792–9.Google Scholar
Nirenberg, MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30: 587–92.Google Scholar
Béreau, M, Fleury, V, Bouthour, W et al. Hyperdopaminergic behavioral spectrum in Parkinson’s disease: a review. Rev. Neurol. (Paris) 2018; 174: 653–63.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×